肿瘤预防与治疗2025，Vol.38Issue(1)：18-26,9.DOI:10.3969/j.issn.1674-0904.2025.01.003
晚期肺癌一线免疫联合治疗症状随访依从性的影响因素分析
Influencing Factors of Symptom Follow-up Adherence in Advanced Lung Cancer Patients Receiving First-Line Immune Checkpoint Inhibitor Com-bination Therapy
摘要
Abstract
Objective:To investigate the influencing factors of symptom follow-up adherence in patients with advanced lung cancer receiving first-line immune checkpoint inhibitor combination therapy based on patient-reported outcomes.Meth-ods:The data of 168 advanced lung cancer patients from multicenter prospective cohort studies between June 2022 and July 2023 were analyzed.The patients were classified into two categories:good adherence(≤24 hours)and poor adherence(＞24 hours),according to the average follow-up length in each week.Multivariate logistic regression was used to analyze factors associated with follow-up adherence.Results:A total of 168 patients were enrolled in this study.Among them,113 were in a good adherence level,55 were in a poor adherence level,with median weekly follow-up length of 14 hours.Univa-riate analysis results indicated that place of residence,education,employment,Eastern Cooperative Oncology Group per-formance status(ECOG-PS)score,Nutritional Risk Screening 2002(NRS-2002)score,pathological type and best overall response were significantly correlated to follow-up adherence(all P＜0.05).Multivariate analysis results further suggested that employment,pathological type,ECOG-PS score and NRS-2002 score were independent influence factors for follow-up ad-herence(all P＜0.05).Conclusion:The follow-up compliance of patients with full-or part-time employment,small cell car-cinoma,ECOG-PS score ≥2 and NRS-2002 score≥3 is poor,and the quality of patient-reported data may be suboptimal.Therefore,the priority should be given to patients with the above characteristics,especially in the timeliness and reliability of follow-up.关键词
肺肿瘤/免疫检查点抑制剂/随访依从性/影响因素/患者报告结局Key words
Lung neoplasms/Immune checkpoint inhibitor/Follow-up adherence/Influencing factor/Patient-reported outcome分类
医药卫生引用本文复制引用
胡瀚,魏星,石丘玲,戴维,周进,贾蓉,王晓珊,郑于珠,王柯,杨帆,熊竹娟,王绎,谢华..晚期肺癌一线免疫联合治疗症状随访依从性的影响因素分析[J].肿瘤预防与治疗,2025,38(1):18-26,9.基金项目
广东省临床试验协会/中国胸部肿瘤研究协作组和广东省肺癌转化医学重点实验室开放课题(编号:YC20210105) （编号:YC20210105）
2022CSCO 重点项目(编号:Y-2021AST/zd-0119) This study was supported by grants from Guangdong Association of Clinical Trials(GACT)/Chinese Tho-racic Oncology Group(CTONG)and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer(No.YC20210105)and Chinese Society of Clinical Oncology(No.Y-2021 AST/zd-0119). （编号:Y-2021AST/zd-0119）
